Jones TE. Oseltamivir - Current dosing recommendations reduce the therapeutic benefit in patients with mild to moderate renal function and/or large body mass. A review of the literature with recommendations to. her Drug Monit. 2020;10.1097/FTD.0000000000000797
Method: Oseltamivir is administered as a pro-drug and converted to the active carboxylate moiety in the liver. Published papers that included Oseltamivir Carboxylate pharmacokinetics in patients with renal impairment and those with large body mass were reviewed. Concentrations of Oseltamivir Carboxylate achieved in the first 24h were compared with those from patients with normal renal function and body mass.
Results: Studies that informed dosage regimens for patients with mild to moderately impaired renal function focussed on attaining steady state concentrations similar to those observed in patients with normal renal function. They overlooked the importance of achieving therapeutic concentrations EARLY in the course of the infection. As a result, many patients will not attain therapeutic concentrations until too late in the infection. This is also true for patients with a large body mass.
Conclusions: Current dosing advice for Oseltamivir in patients with mild to moderate renal impairment and those with a larger body mass are likely to reduce (or even negate) its efficacy. The first dose should be 75mg for patients with normal body mass and proportionately larger when body mass is larger. Subsequent doses should be reduced in proportion to the degree of renal impairment. Timely therapeutic drug monitoring can provide invaluable dosing (and other) information to the clinician treating patients with Influenza and could improve patient outcomes.
- Influenza A Virus Inhibits RSV Infection via a Two-Wave Expression of IFIT Proteins 2 days ago
- Identification of Linear Peptide Immunogens with Verified Broad-spectrum Immunogenicity from the Conserved Regions within the Hemagglutinin Stem Domain of H1N1 Influenza Virus 3 days ago
- Antibody Responses Against Equine Influenza Virus Induced by Concurrent and by Consecutive Use of an Inactivated Equine Influenza Virus Vaccine and a Modified Live Equine Herpesvirus Type 1 Vaccine in 3 days ago
- Evaluation of cobas Influenza A/B & RSV Test for Diagnosis of Equine Influenza 3 days ago
- Risk conditions in children hospitalized with influenza in Norway, 2017~2019 3 days ago